Dr. Petra Hamerlik is the Chair of Translational Neuro-Oncology at the University of Manchester. She previously served as Principal Scientist and CNS Cancer Bioscience Lead at AstraZeneca, where she ...

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and the ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les actus Santé à ne pas manquer !

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les actus Santé à ne pas manquer !

The Tecan Group (SIX Swiss Exchange: TECN) today announced a planned CEO transition, marking a new chapter in the company’s successful growth story. After nearly 12 years with Tecan, including 6 ½ ...

ExpertCare featured in Innovate UK Research Project ...

Effective from 1 October 2025, CMS and commercial health insurers will recognise the HCPCS Level II code A9616 assigned for reimbursement of Gozellix. The assignment of the code is a significant ...

About the Setrusumab Phase 3 Program Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 ...

The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into ...

ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company.

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.